Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging
- 27 February 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1111) , 20190832
Abstract
18F-Fluorodeoxyglucose positron emission tomography/CT imaging plays a key role in oncological imaging including in staging, radiotherapy planning, treatment response and recurrence assessment. Immunotherapies represent a major advance in cancer therapy for a number of tumours with resulting survival benefit. However, a wide range of immune related adverse events (irAEs), some of which can be apparent on imaging, have been reported. These involve many organ systems but particularly endocrine, cutaneous and gastrointestinal systems. Early detection of irAEs is essential to aid diagnosis and management of patients and to reduce associated morbidity. In addition, it is important to not mistake treatment related effects for disease. This pictorial review aims to identify common irAEs and changes seen on 18F-fluorodeoxyglucose positron emission tomography/CT.Keywords
This publication has 29 references indexed in Scilit:
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Management of toxicities of immune checkpoint inhibitorsCancer Treatment Reviews, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitisAbdominal Radiology, 2015
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with IpilimumabCancer Immunology Research, 2015
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insightsPituitary, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Strikingly high false positivity of surveillance FDG‐PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab eraAmerican Journal of Hematology, 2013
- Cancer immunotherapy comes of ageNature, 2011
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009